For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
As of close of business last night, Verona Pharma Plc ADR’s stock clocked out at $72.07, down -1.56% from its previous closing price of $73.21. In other words, the price has decreased by -$1.56 from its previous closing price. On the day, 1.47 million shares were traded. VRNA stock price reached its highest trading level at $74.145 during the session, while it also had its lowest trading level at $71.33.
Ratios:
To gain a deeper understanding of VRNA’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 10.48 and its Current Ratio is at 10.63. In the meantime, Its Debt-to-Equity ratio is 0.60 whereas as Long-Term Debt/Eq ratio is at 0.59.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, TD Cowen on April 28, 2025, initiated with a Buy rating and assigned the stock a target price of $100.
On April 21, 2025, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $80.
On January 10, 2025, ROTH MKM started tracking the stock assigning a Buy rating and target price of $68.ROTH MKM initiated its Buy rating on January 10, 2025, with a $68 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Apr 29 ’25 when VIKAS SINHA bought 20,000 shares for $68.83 per share.
Rickard Kathleen A. sold 79,264 shares of VRNA for $661,942 on Mar 12 ’25. The Chief Medical Officer now owns 2,608,976 shares after completing the transaction at $8.35 per share. On Mar 12 ’25, another insider, KATHLEEN RICKARD, who serves as the Officer of the company, bought 9,908 shares for $62.70 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VRNA now has a Market Capitalization of 9593021440 and an Enterprise Value of 48824475648. For the stock, the TTM Price-to-Sale (P/S) ratio is 135.75 while its Price-to-Book (P/B) ratio in mrq is 29.82. Its current Enterprise Value per Revenue stands at 411.899 whereas that against EBITDA is -365.257.
Stock Price History:
The Beta on a monthly basis for VRNA is 0.20, which has changed by 3.575873 over the last 52 weeks, in comparison to a change of 0.09969199 over the same period for the S&P500. Over the past 52 weeks, VRNA has reached a high of $74.18, while it has fallen to a 52-week low of $11.39. The 50-Day Moving Average of the stock is 13.92%, while the 200-Day Moving Average is calculated to be 66.02%.
Shares Statistics:
It appears that VRNA traded 1.48M shares on average per day over the past three months and 1623590 shares per day over the past ten days. A total of 84.63M shares are outstanding, with a floating share count of 69.35M. Insiders hold about 12.34% of the company’s shares, while institutions hold 75.64% stake in the company. Shares short for VRNA as of 1744675200 were 7778024 with a Short Ratio of 5.27, compared to 1741910400 on 9848197. Therefore, it implies a Short% of Shares Outstanding of 7778024 and a Short% of Float of 9.54.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
